Collin F Payne1, Brian Houle2, Chido Chinogurei3, Carlos Riumallo Herl4, Chodziwadziwa Whiteson Kabudula5, Lindsay C Kobayashi6, Joshua A Salomon7, Jennifer Manne-Goehler8. 1. School of Demography, Research School of Social Sciences, The Australian National University, Canberra, ACT, Australia; Center for Population and Development Studies, Harvard T H Chan School of Public Health, Cambridge, MA, USA. Electronic address: collin.payne@anu.edu.au. 2. School of Demography, Research School of Social Sciences, The Australian National University, Canberra, ACT, Australia; MRC/Wits Rural Public Health and Heath Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. 3. Centre for Infectious Diseases and Epidemiology Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 4. School of Economics, Erasmus University, Rotterdam, Netherlands. 5. MRC/Wits Rural Public Health and Heath Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. 6. Center for Social Epidemiology and Population Health, Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 7. Center for Primary Care and Outcomes Research, Stanford University, Palo Alto, CA, USA. 8. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Center for Population and Development Studies, Harvard T H Chan School of Public Health, Cambridge, MA, USA.
Abstract
BACKGROUND: The population of people living with HIV in South Africa is rapidly ageing due to increased survivorship attributable to antiretroviral therapy (ART). We sought to understand how the combined effects of HIV and ART have led to differences in healthy longevity by HIV status and viral suppression in this context. METHODS: In this observational cohort modelling study we use longitudinal data from the 2015 baseline interview (from Nov 13, 2014, to Nov 30, 2015) and the 2018 longitudinal follow-up interview (from Oct 12, 2018, to Nov 7, 2019) of the population-based study Health and Ageing in Africa: a Longitudinal Study of an INDEPTH Community in South Africa (HAALSI) to estimate life expectancy and disability-free life expectancy (DFLE) of adults aged 40 years and older in rural South Africa. Respondents who consented to HIV testing, responded to survey questions on disability, and who were either interviewed in both surveys or who died between survey waves were included in the analysis. We estimate life expectancy and DFLE by HIV status and viral suppression (defined as <200 copies per mL) using Markov-based microsimulation. FINDINGS: Among the 4322 eligible participants from the HAALSI study, we find a clear gradient in remaining life expectancy and DFLE based on HIV serostatus and viral suppression. At age 45 years, the life expectancy of a woman without HIV was 33·2 years (95% CI 32·0-35·0), compared with 31·6 years (29·2-34·1) a woman with virally suppressed HIV, and 26·4 years (23·1-29·1) for a woman with unsuppressed HIV; life expectancy for a 45 year old man without HIV was 27·2 years (25·8-29·1), compared with 24·1 years (20·9-27·2) for a man with virally suppressed HIV, and 17·4 years (15·0-20·3) for a man with unsuppressed HIV. Men and women with viral suppression could expect to live nearly as many years of DFLE as HIV-uninfected individuals at ages 45 years and 65 years. INTERPRETATION: These results highlight the tremendous benefits of ART for population health in high-HIV-prevalence contexts and reinforce the need for continued work in making ART treatment accessible to ageing populations. FUNDING: National Institutes of Health.
BACKGROUND: The population of people living with HIV in South Africa is rapidly ageing due to increased survivorship attributable to antiretroviral therapy (ART). We sought to understand how the combined effects of HIV and ART have led to differences in healthy longevity by HIV status and viral suppression in this context. METHODS: In this observational cohort modelling study we use longitudinal data from the 2015 baseline interview (from Nov 13, 2014, to Nov 30, 2015) and the 2018 longitudinal follow-up interview (from Oct 12, 2018, to Nov 7, 2019) of the population-based study Health and Ageing in Africa: a Longitudinal Study of an INDEPTH Community in South Africa (HAALSI) to estimate life expectancy and disability-free life expectancy (DFLE) of adults aged 40 years and older in rural South Africa. Respondents who consented to HIV testing, responded to survey questions on disability, and who were either interviewed in both surveys or who died between survey waves were included in the analysis. We estimate life expectancy and DFLE by HIV status and viral suppression (defined as <200 copies per mL) using Markov-based microsimulation. FINDINGS: Among the 4322 eligible participants from the HAALSI study, we find a clear gradient in remaining life expectancy and DFLE based on HIV serostatus and viral suppression. At age 45 years, the life expectancy of a woman without HIV was 33·2 years (95% CI 32·0-35·0), compared with 31·6 years (29·2-34·1) a woman with virally suppressed HIV, and 26·4 years (23·1-29·1) for a woman with unsuppressed HIV; life expectancy for a 45 year old man without HIV was 27·2 years (25·8-29·1), compared with 24·1 years (20·9-27·2) for a man with virally suppressed HIV, and 17·4 years (15·0-20·3) for a man with unsuppressed HIV. Men and women with viral suppression could expect to live nearly as many years of DFLE as HIV-uninfected individuals at ages 45 years and 65 years. INTERPRETATION: These results highlight the tremendous benefits of ART for population health in high-HIV-prevalence contexts and reinforce the need for continued work in making ART treatment accessible to ageing populations. FUNDING: National Institutes of Health.
Authors: Bongani M Mayosi; Alan J Flisher; Umesh G Lalloo; Freddy Sitas; Stephen M Tollman; Debbie Bradshaw Journal: Lancet Date: 2009-08-24 Impact factor: 79.321
Authors: Jan A C Hontelez; Sake J de Vlas; Rob Baltussen; Marie-Louise Newell; Roel Bakker; Frank Tanser; Mark Lurie; Till Bärnighausen Journal: AIDS Date: 2012-07-31 Impact factor: 4.177
Authors: Julia K Rohr; Jennifer Manne-Goehler; Francesc Xavier Gómez-Olivé; Ryan G Wagner; Molly Rosenberg; Pascal Geldsetzer; Chodziwadziwa Kabudula; Kathleen Kahn; Stephen Tollman; Till Bärnighausen; Joshua A Salomon Journal: Sex Transm Infect Date: 2019-06-26 Impact factor: 3.519
Authors: Jennifer Manne-Goehler; Julia Rohr; Livia Montana; Mark Siedner; Guy Harling; F Xavier Gómez-Olivé; Pascal Geldsetzer; Ryan Wagner; Lubbe Wiesner; Kathleen Kahn; Stephen Tollman; Till W Bärnighausen Journal: AIDS Behav Date: 2019-08
Authors: Margaret T May; Mark Gompels; Valerie Delpech; Kholoud Porter; Chloe Orkin; Stephen Kegg; Phillip Hay; Margaret Johnson; Adrian Palfreeman; Richard Gilson; David Chadwick; Fabiola Martin; Teresa Hill; John Walsh; Frank Post; Martin Fisher; Jonathan Ainsworth; Sophie Jose; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin Journal: AIDS Date: 2014-05-15 Impact factor: 4.177
Authors: Georges Reniers; Sylvia Blom; Clara Calvert; Alexandra Martin-Onraet; Abraham J Herbst; Jeffrey W Eaton; Jacob Bor; Emma Slaymaker; Zehang R Li; Samuel J Clark; Till Bärnighausen; Basia Zaba; Victoria Hosegood Journal: Lancet HIV Date: 2016-12-10 Impact factor: 16.070